Literature DB >> 10074186

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.

M E Major1, K Mihalik, J Fernandez, J Seidman, D Kleiner, A A Kolykhalov, C M Rice, S M Feinstone.   

Abstract

Two chimpanzees (Ch1535 and Ch1536) became infected with hepatitis C virus (HCV) following intrahepatic inoculation with RNA transcribed from a full-length cDNA clone of the virus. Both animals were persistently infected and have been followed for 60 weeks. They showed similar responses to infection, with transient liver enzyme elevations and liver inflammatory responses, which peaked at weeks 17 (Ch1535) and 12 (Ch1536) postinoculation (p.i.). Antibody responses to structural and nonstructural proteins were first detected at weeks 13 (Ch1535) and 10 (Ch1536) p.i. Serum RNA titers increased steadily during the first 10 to 13 weeks but decreased sharply in both animals following antibody and inflammatory responses. Despite direct evidence of humoral immune responses to multiple viral antigens, including hypervariable region 1 (HVR1), both animals remained chronically infected. Detailed sequence analysis of serum HCV RNA revealed no change in the majority HVR1 sequence in Ch1535 and a single-amino-acid mutation in Ch1536, with very little clonal variation in either animal. Full-length genome analysis at week 60 revealed several amino acid substitutions localized to antigens E1, E2, p7, NS3, and NS5. Of these, 55.6 and 40% were present as the majority sequence in serum RNA isolated at week 26 p.i. (Ch1535) and week 22 p.i. (Ch1536), respectively, and could represent immune escape mutations. Mutations accumulated at a rate of 1.57 x 10(-3) and 1.48 x 10(-3) nucleotide substitutions/site/year for Ch1535 and Ch1536, respectively. Taken together, these data indicate that establishment of a persistent HCV infection in these chimpanzees is not due to changes in HVR1; however, the possibility remains that mutations arising in other parts of the genome contributed to this persistence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074186      PMCID: PMC104096     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.

Authors:  K M Chang; B Rehermann; J G McHutchison; C Pasquinelli; S Southwood; A Sette; F V Chisari
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

2.  Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection.

Authors:  C A Wyatt; L Andrus; B Brotman; F Huang; D H Lee; A M Prince
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.

Authors:  N Kato; H Sekiya; Y Ootsuyama; T Nakazawa; M Hijikata; S Ohkoshi; K Shimotohno
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus.

Authors:  N Kato; Y Ootsuyama; S Ohkoshi; T Nakazawa; H Sekiya; M Hijikata; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

5.  Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis.

Authors:  M J Koziel; D Dudley; J T Wong; J Dienstag; M Houghton; R Ralston; B D Walker
Journal:  J Immunol       Date:  1992-11-15       Impact factor: 5.422

6.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

7.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

8.  Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses.

Authors:  L J van Doorn; I Capriles; G Maertens; R DeLeys; K Murray; T Kos; H Schellekens; W Quint
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.

Authors:  A Cerny; J G McHutchison; C Pasquinelli; M E Brown; M A Brothers; B Grabscheid; P Fowler; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  44 in total

1.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

2.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes.

Authors:  Catherine A Lázaro; Ming Chang; Weiliang Tang; Jean Campbell; Daniel G Sullivan; David R Gretch; Lawrence Corey; Robert W Coombs; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.

Authors:  Xiping Zhao; Zhen-Ya Tang; Bettina Klumpp; Guido Wolff-Vorbeck; Heidi Barth; Shoshana Levy; Fritz von Weizsäcker; Hubert E Blum; Thomas F Baumert
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

5.  Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees.

Authors:  Iryna Zubkova; Hongying Duan; Frances Wells; Howard Mostowski; Esther Chang; Kathleen Pirollo; Kris Krawczynski; Robert Lanford; Marian Major
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

6.  Profile of Charles M. Rice.

Authors:  Prashant Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

Review 7.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

Review 8.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.

Authors:  Javier Fernandez; Deborah Taylor; Duncan R Morhardt; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Stephen M Feinstone; Marian E Major
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins.

Authors:  Shingo Takikawa; Ronald E Engle; Kristina N Faulk; Suzanne U Emerson; Robert H Purcell; Jens Bukh
Journal:  J Gen Virol       Date:  2009-11-11       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.